Skip to main content
Log in

Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The relationships between alprazolam and metabolite concentrations and CNS effects were determined in a double-blind placebo controlled four-way crossover trial in 16 normal male volunteers. Active drug treatments consisted of 4-day regimens of 4 mg alprazolam PO daily as 2 mg bid., 1 mg qid, and 0.25 mg each hour. On days 1 and 4, the kinetics, sedative and psychomotor effects were evaluated. Plasma concentrations of the 4- and α-hydroxy metabolites of alprazolam were less than 10% of unchanged alprazolam levels on both days. Accumulation of these metabolites and alprazolam was dependent on alprazolam half-life (11.6 h). Acute and chronic tolerance to the sedative and psychomotor effects was observed with all active drug treatments. All alprazolam treatments resulted in significantly greater sedation than placebo on days 1 and 4. However, on day 4, sedation was 16–36% less than observed on day 1, despite plasma concentrations 1.4–2.76 times the day 1 concentrations. Sedation from alprazolam was reduced in each successive study phase, suggesting a tolerance which was sustained during the 10-day washout between phases. By day 4, psychomotor performance was not different from placebo, indicating more complete development of tolerance than occurred for the sedative effect. Sedation and psychomotor impairment on day 1 were greatest with 2 mg alprazolam bid. During the initiation of therapy, the patient will likely experience less sedation and psychomotor impairment with smaller, more frequent doses. Since tolerance develops to these effects, the advantage of more frequent dosing regimen dissipates by the 4th day.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Aranko K (1985) Task-dependent development of cross-tolerance to psychomotor effects of lorazepam in man. Acta Pharmacol Toxicol 56:373–381

    Article  CAS  Google Scholar 

  • Aranko K, Mattila MJ, Seppala T (1983) Development of tolerance and cross-tolerance to the psychomotor actions of lorazepam and diazepam in man. Br J Clin Pharmacol 15:545–552

    PubMed  CAS  Google Scholar 

  • Chouinard G, Annable L, Fontaine R, Solyom L (1982) Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind placebo-controlled study. Psychopharmacology 77:229–233

    Article  PubMed  CAS  Google Scholar 

  • Cohn JB (1981) Multicenter double-blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients. J Clin Psychiatry 42:347–351

    PubMed  CAS  Google Scholar 

  • Dixon WJ, editor (1983) BMPD Statistical Software. University of California Press, Los Angeles

    Google Scholar 

  • Ellinwood EH, Heatherly DG, Nikaido AM, Bjornsson TD, Kilts C (1985) Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology 86:392–399

    Article  PubMed  Google Scholar 

  • Fabre LF, Mclendon DM (1980) A double-blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression. Curr Ther Res Clin Exp 27:474–482

    Google Scholar 

  • Feighner JP, Aden GC, Fabre LF (1983) Multicenter double-blind safety and efficacy comparison of alprazolam, imipramine and placebo in the treatment of major depressive disorder. JAMA 249:3057–3064

    Article  PubMed  CAS  Google Scholar 

  • File AE, Lister RG (1983) Does tolerance to larozepam develop with once weekly dosing? Br J Clin Pharmacol 16:645–650

    PubMed  CAS  Google Scholar 

  • Gall M, Kamdar BV, Collins RJ (1978) Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple one-step oxidation of benzodiazepines. J Med Chem 21:1290–1294

    Article  PubMed  CAS  Google Scholar 

  • Ghoneim MM, Hinrichs JV, Mewaldt SP (1986) Comparison of two benzodiazepines with differing accumulation: Behavioral changes during and after three weeks of dosing. Clin Pharmacol Ther 39:491–500

    Article  PubMed  CAS  Google Scholar 

  • Greenblatt DJ, Divoll M, Moschitto LJ, Smith RB, Shader RI (1983) Alprazolam kinetics in the elderly. Arch Gen Psychiatry 40:287–290

    PubMed  CAS  Google Scholar 

  • Hengen N, Hoffman E, Schick C (1982) Liquid chromatographic assay of the new benzodiazepine derivative GP 55129 in plasma and urine after application to humans. Naunyn-Schmiedberg's Arch Pharmacol [Suppl] 319:R88 (Abstr)

  • Johnson LC, Chernik DA (1982) Sedative-hypnotic and human performance. Psychopharmacology 76:101–113

    Article  PubMed  CAS  Google Scholar 

  • Ochs HR, Greenblatt DJ, Luttkenhorst M, and Verburg-Ochs (1984) Single and Multiple dose kinetics of clobazam, and clinical effects during multiple dosage. Eur J Clin Pharmacol 26:499–503

    Article  PubMed  CAS  Google Scholar 

  • SAS Institute Inc (1985) SAS user's Guide: Statistics, Version 5 Edition. Cary, NC

    Google Scholar 

  • Seidel WF, Cohen SA, Wilson L, Dement WC (1985) Effects of alprazolam and diazepam on daytime sleepiness of non-anxious subjects. Psychopharmacology 87:194–197

    Article  PubMed  CAS  Google Scholar 

  • Sethy VH, Harris DW (1982) Determination of biological activity of alprazolam, triazolam and their metabolites. J Pharm Pharmacol 34:115–116

    PubMed  CAS  Google Scholar 

  • Smith RB, Gwilt PR, Wright CE (1983) Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Clin Pharm 2:139–143

    PubMed  CAS  Google Scholar 

  • Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 1984; 84:452–456

    Article  PubMed  CAS  Google Scholar 

  • Wechsler D (1955) A manual for the Wechsler Adult Intelligence Scale. New York, Psychological Corporation

    Google Scholar 

  • Winer BJ (1971) Statistical principles in experimental design, edn 2. McGraw-Hill, New York

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, R.B., Kroboth, P.D. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology 93, 105–112 (1987). https://doi.org/10.1007/BF02439595

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02439595

Key words

Navigation